Financial Results for FY2024 Supplement

May 12, 2025
SHIONOGI & CO., LTD.

1. Consolidated statement of profit or loss

(Billions of yen)

	FY2023	FY2024	Change	Change (%)	Comment	FY2024 forecast	Progress (%)	FY2025 forecast	Change
Revenue	435.1	438.3	3.2	0.7	Increasing/(decreasing) in Prescription drugs (52.4) billion Overseas subsidiaries/Export 9.2billion Royalty income 44.3billion	460.0	95.3	530.0	91.7
Cost of sales	(57.6)	(63.8)	6.2	10.8		(67.0)	95.3	(89.0)	25.2
Gross profit	377.5	374.4	(3.0)	(0.8)		393.0	95.3	441.0	66.6
SG&A expenses	(99.7)	(101.9)	2.2	2.2		(104.7)	97.3	(126.8)	24.9
R&D expenses	(102.6)	(108.6)	6.0	5.8	Investments in major development projects and foreign exchange effects	(116.0)	93.6	(131.0)	22.4
Amortization of intangible assets associated with products	(3.7)	(4.2)	0.4	12.1		(4.3)	97.2	(4.2)	0.0
Other income	6.2	0.5	(5.7)	(91.5)					
Other expenses	(24.3)	(3.7)	(20.6)	(84.8)	FY2023 : Impairment losses on in-process research and development assets and expenses relating to the implementation of a special early retirement program	(3.0)	105.8	(4.0)	0.8
Operating profit	153.3	156.6	3.3	2.1		165.0	94.9	175.0	18.4
Finance income	51.7	53.2	1.5	2.9		41.0	107.7	47.0	2.9
Finance costs	(6.7)	(9.0)	2.3	34.7					
Profit before tax	198.3	200.8	2.5	1.2		206.0	97.5	222.0	21.2
Income tax expense	(37.7)	(31.2)	(6.5)	(17.2)					
Profit	160.6	169.5	9.0	5.6					
Profit attributable to									
Owners of parent	162.0	170.4	8.4	5.2		171.0	99.7	180.0	9.6
Non-controlling interests	(1.5)	(0.9)	(0.6)	(38.1)					
Profit	160.6	169.5	9.0	5.6					

*Revenue for FY2023 includes Lump-sum income for transfer of ADHD drug.

Reconciliation from operating profit to EBITDA

(Billions of yen)

	FY2023	FY2024
Operating profit	153.3	156.6
Other income	(5.9)	(0.2)
Other expenses	23.0	2.0
Core operating profit *1	170.4	158.4
Depreciation and amortization	18.3	20.9
EBITDA *2	188.7	179.3

*1. Core operating profit: An adjusted profit in which non-recurring items (impairment, gain on sales of property, plant, and equipment, etc.) are deducted from operating profit.
2. Earnings Before Interest, Taxes, Depreciation and Amortization: Core operating profit added depreciation and amortization.

2. Revenue by segment

FY2024 actual

(Billions of yen)

	FY2023	FY2024	Change	Change(%)	FY2024 forecast	Progress(%)
Prescription drugs	151.1	98.8	(52.4)	(34.6)	124.7	79.2
Infectious Disease Drugs	82.9	61.4	(21.6)	(26.0)	83.4	73.6
COVID-19 related products + Influenza Franchise	73.4	51.8	(21.6)	(29.5)	72.3	71.6
SYMPROIC	4.5	5.0	0.5	11.1	5.9	85.1
OXYCONTIN Franchise	4.2	4.3	0.1	2.4	5.0	85.0
ACTAIR	0.7	0.9	0.2	22.9	1.3	66.0
CYMBALTA	3.8	2.1	(1.7)	(44.7)	3.3	64.1
Others	55.0	25.2	(29.8)	(54.2)	25.8	97.4
QUVIVIQ	-	0.8	0.8	-	3.0	26.5
Overseas subsidiaries/Export	49.9	59.1	9.2	18.4	57.6	102.6
Shionogi Inc. (US)	17.9	23.4	5.5	30.6	22.6	103.4
Shionogi B.V. (EU)	13.6	16.8	3.3	24.0	16.7	100.7
Ping An-Shionogi / C&O	10.6	8.7	(1.9)	(18.3)	9.1	95.3
Others	7.8	10.2	2.4	30.3	9.2	111.0
Contract manufacturing	17.6	17.3	(0.4)	(2.0)	16.5	104.6
OTC and quasi-drugs	14.6	16.8	2.2	14.8	16.6	101.3
Royalty income	200.4	244.7	44.3	22.1	242.8	100.8
HIV Franchise	195.8	240.4	44.6	22.8	234.9	102.3
Others	4.6	4.3	(0.3)	(6.8)	7.9	54.0
Others	1.4	1.7	0.2	17.0	1.8	93.4
Total	435.1	438.3	3.2	0.7	460.0	95.3

*1. Sales of prescription drugs are shown on non-consolidated basis.
2. Products included in Infectious Disease Drugs: Xocova, Xofluza, Rapiacta, Brightpoc Flu Neo, Finibax, Flumarin, Flomox, Shiomarin, Baktar, Flagyl, Isodine, Fetroja
3. Others in prescription drugs for FY2023 include Lump-sum income for transfer of ADHD drug.

FY2025 forecast

(Billions of yen)

	FY2024	FY2025 forecast	Change
Prescription drugs	98.8	183.0	84.2
Acute Respiratory Virus Infection Treatment	51.8	85.8	34.0
QUVIVIQ	0.8	9.3	8.5
SYMPROIC	5.0	8.1	3.1
OXYCONTIN Franchise	4.3	5.6	1.3
Others	36.9	74.2	37.3
Overseas subsidiaries/Export	59.1	54.9	(4.2)
Shionogi Inc. (US)	23.4	22.6	(0.8)
Shionogi B.V. (EU)	16.8	16.9	0.1
Shionogi China	8.7	7.0	(1.7)
Others	10.2	8.4	(1.8)
Contract manufacturing	17.3	13.2	(4.1)
OTC and quasi-drugs	16.8	18.5	1.7
Royalty income	244.7	257.9	13.2
HIV Franchise	240.4	244.8	4.4
Others	4.3	13.1	8.8
Others	1.7	2.5	0.8
Total	438.3	530.0	91.7

*1. Sales of prescription drugs are shown on non-consolidated basis.
2. Products included in Acute Respiratory Virus Infection Treatment: COVID-19 Treatment "Xocova", Influenza Franchise "Xofluza" and "Rapiacta"

3. Quarterly trend (Consolidated statement of profit or loss)

(Billions of yen)

	FY2023				FY2024							
	1Q	2Q	3Q	4Q	1Q	Y on Y change (%)	2Q	Y on Y change (%)	3Q	Y on Y change (%)	4Q	Y on Y change (%)
Revenue	109.3	121.2	106.3	98.3	97.6	(10.7)	116.4	(4.0)	119.6	12.6	104.7	6.5
Cost of sales	(13.1)	(14.8)	(14.5)	(15.2)	(14.4)	10.1	(15.7)	6.3	(15.9)	9.5	(17.8)	17.0
Gross profit	96.2	106.5	91.8	83.1	83.1	(13.6)	100.7	(5.4)	103.7	13.0	86.9	4.6
SG&A expenses	(23.2)	(24.3)	(24.1)	(28.0)	(24.0)	3.7	(23.7)	(2.6)	(25.5)	5.4	(28.7)	2.5
R&D expenses	(25.0)	(22.2)	(25.4)	(30.0)	(29.4)	17.7	(27.4)	23.4	(22.6)	(11.0)	(29.2)	(2.8)
Amortization of intangible assets associated with products	(0.8)	(0.9)	(0.9)	(1.1)	(1.1)	28.9	(1.1)	21.6	(1.1)	22.0	(0.9)	(16.5)
Other income	0.1	0.1	0.2	5.8	0.1	(16.6)	0.4	330.4	0.0	(90.5)	0.0	(99.5)
Other expenses	(0.7)	(7.6)	(0.8)	(15.2)	(0.5)	(18.0)	(1.2)	(84.5)	(1.2)	46.6	(0.8)	(95.1)
Operating profit	46.6	51.5	40.6	14.6	28.1	(39.7)	47.8	(7.3)	53.4	31.3	27.4	87.9
Finance income	10.1	10.6	11.4	21.9	11.3	11.7	13.9	31.4	10.2	(10.5)	21.0	(4.2)
Finance costs	(1.0)	(2.2)	(3.1)	(2.7)	(2.8)	197.5	(4.4)	97.3	(1.5)	(52.3)	(3.5)	30.0
Profit before tax	55.7	59.9	48.9	33.8	36.5	(34.4)	57.3	(4.3)	62.0	26.9	44.9	32.8
Income tax expense	(13.5)	(11.9)	(12.6)	0.3	(6.2)	(53.9)	(4.7)	(60.2)	(11.6)	(8.4)	(8.7)	-
Profit	42.2	48.0	36.2	34.1	30.3	(28.2)	52.6	9.5	50.5	39.2	36.2	6.0
Profit attributable to												
Owners of parent	42.6	48.0	36.6	34.8	30.6	(28.0)	52.5	9.3	50.7	38.3	36.6	5.2
Non-controlling intersts	(0.3)	(0.0)	(0.4)	(0.7)	(0.3)	(5.0)	0.1	-	(0.2)	(47.2)	(0.4)	(35.3)
Profit	42.2	48.0	36.2	34.1	30.3	(28.2)	52.6	9.5	50.5	39.2	36.2	6.0

* Revenue for FY2023 includes Lump-sum income for transfer of ADHD drug.

4. Quarterly trend (Revenue by segment)

(Billions of yen)

	FY2023				FY2024							
	1Q	2Q	3Q	4Q	1Q	Y on Y change (%)	2Q	Y on Y change (%)	3Q	Y on Y change (%)	4Q	Y on Y change (%)
Prescription drugs	45.9	50.4	31.2	23.6	15.4	(66.4)	32.3	(36.0)	31.2	0.2	19.8	(16.0)
Infectious Disease Drugs	9.3	39.8	20.0	13.9	6.1	(34.4)	23.1	(41.8)	20.8	4.0	11.3	(18.5)
COVID-19 related products + Influenza Franchise	7.1	37.3	17.6	11.4	3.9	(44.9)	21.0	(43.9)	18.5	4.8	8.5	(25.5)
SYMPROIC	1.0	1.1	1.2	1.2	1.1	6.0	1.3	19.4	1.5	19.9	1.2	(0.9)
OXYCONTIN Franchise	1.1	1.1	1.1	0.8	1.0	(6.7)	1.0	(4.4)	1.2	9.5	0.9	13.5
ACTAIR	0.1	0.2	0.2	0.2	0.2	43.9	0.2	24.9	0.3	19.0	0.2	9.2
CYMBALTA	1.1	1.0	1.0	0.7	0.8	(27.0)	0.7	(32.7)	0.4	(61.9)	0.3	(63.8)
Others	33.3	7.4	7.5	6.8	6.2	(81.3)	6.0	(19.2)	7.1	(6.6)	5.9	(12.7)
QUVIVIQ	–	–	–	–	–	–	–	–	0.5	–	0.3	–
Overseas subsidiaries/Export	12.0	10.9	13.6	13.4	15.0	24.9	13.4	22.0	15.0	10.8	15.7	17.2
Shionogi Inc. (US)	4.0	4.1	5.0	4.8	6.0	48.6	5.2	27.4	6.3	26.6	5.9	22.5
Shionogi B.V. (EU)	3.0	3.1	4.0	3.5	4.0	34.2	4.3	37.1	4.6	17.3	3.9	11.0
Ping An-Shionogi / C&O	3.1	2.2	3.0	2.3	2.3	(25.8)	1.9	(11.6)	2.1	(32.0)	2.4	3.7
Others	1.9	1.6	1.6	2.8	2.7	42.9	1.9	23.9	2.1	27.4	3.5	27.1
Contract manufacturing	4.0	3.9	3.8	5.9	3.6	(10.4)	4.2	6.3	2.9	(22.9)	6.6	11.7
OTC and quasi-drugs	2.3	4.8	3.5	4.1	2.4	6.6	5.7	19.1	4.5	30.0	4.1	1.2
Royalty income	44.8	50.8	53.5	51.3	61.0	36.1	60.5	19.2	65.3	22.0	57.9	13.0
HIV Franchise	44.3	50.2	51.6	49.7	59.8	35.1	59.8	19.1	63.9	23.9	56.9	14.5
Others	0.6	0.5	1.9	1.6	1.2	109.6	0.7	27.3	1.4	(28.9)	1.0	(35.1)
Others	0.3	0.3	0.7	0.1	0.2	(44.1)	0.4	0.8	0.6	(16.8)	0.6	706.9
Total	109.3	121.2	106.3	98.3	97.6	(10.7)	116.4	(4.0)	119.6	12.6	104.7	6.5

*1. Sales of prescription drugs are shown on non-consolidated basis.
2. Products included in Infectious Disease Drugs: Xocova, Xofluza, Rapiacta, Brightpoc Flu Neo, Finibax, Flumarin, Flomox, Shiomarin, Baktar, Flagyl, Isodine, Fetroja
3. Others in prescription drugs for FY2023 include Lump-sum income for transfer of ADHD drug.

5. Consolidated statement of financial position

(Billions of yen)

	As of Mar. 31 2024	As of Mar. 31 2025	Y on Y change	Comment
Assets				
Non-current assets				
Property, plant and equipment	114.6	115.4	0.8	
Goodwill	15.3	15.7	0.5	
Intangible assets	117.6	143.7	26.0	Increase due to acquisition of in-process research and development assets
Right-of-use assets	9.4	19.4	10.0	Increase in right-of-use assets relating to the new Head Office
Investment property	27.8	27.7	(0.0)	
Other financial assets	292.3	299.8	7.5	
Deferred tax assets	13.5	13.2	(0.3)	
Other non-current assets	42.2	41.9	(0.3)	
Total non-current assets	632.7	676.8	44.1	
Current assets				
Inventories	64.9	65.5	0.6	
Trade receivables	122.8	120.6	(2.3)	
Other financial assets	215.8	270.0	54.3	Increase in time deposits over 3 months
Other current assets	22.6	27.7	5.0	
Cash and cash equivalents	358.1	374.8	16.7	
Total current assets	784.2	858.5	74.3	
Total assets	1,416.9	1,535.3	118.4	

Equity and liabilities				
Equity				
Share capital	21.3	21.3	–	
Capital surplus	14.2	17.8	3.6	
Treasury shares	(137.9)	(65.9)	(72.0)	Cancellation of treasury shares
Retained earnings	1,065.9	1,115.7	49.8	
Other components of equity	271.8	272.9	1.1	
Equity attributable to owners of parent	1,235.3	1,361.9	126.6	
Non-controlling interests	17.2	0.6	(16.7)	
Total equity	1,252.6	1,362.5	109.9	
Liabilities				
Non-current liabilities				
Lease liabilities	8.8	18.4	9.7	Increase in lease liabilities relating to the new Head Office
Other financial liabilities	7.6	8.3	0.6	
Retirement benefit liability	8.0	8.0	0.0	
Deferred tax liabilities	4.4	4.4	0.0	
Other non-current liabilities	1.7	4.4	2.7	
Total non-current liabilities	30.4	43.5	13.0	
Current liabilities				
Lease liabilities	2.9	3.5	0.6	
Trade payables	14.8	13.6	(1.2)	
Other financial liabilities	31.1	18.1	(13.0)	
Income taxes payable	20.8	22.4	1.6	
Other current liabilities	64.3	71.9	7.6	
Total current liabilities	133.9	129.4	(4.5)	
Total liabilities	164.4	172.9	8.5	
Total equity and liabilities	1,416.9	1,535.3	118.4	

6. Management index

		FY2023				FY2024			
		Apr.-Jun.	Apr.-Sep.	Apr.-Dec.	Apr.-Mar.	Apr.-Jun.	Apr.-Sep.	Apr.-Dec.	Apr.-Mar.
STS2030 Revision Growth									
Revenue *1	Billions of yen	109.3	230.5	336.8	435.1	97.6	214.0	333.6	438.3
Overseas sales CAGR *2	%	-	-	-	17.4	-	-	-	17.9
EBITDA	Billions of yen	51.3	114.2	160.2	188.7	33.1	86.7	146.4	179.3
STS2030 Revision Shareholder return									
Basic earnings per share *3	yen	48.21	102.88	145.30	186.17	36.02	97.74	157.30	200.36
Diluted earnings per share *3	yen	48.19	102.85	145.25	186.11	36.01	97.70	157.25	200.29
Ratio of dividends to equity attributable to owners of parent (DOE)	%	-	-	-	4.0	-	-	-	4.0
Return on equity attributable to owners of parent (ROE)	%	3.7	7.8	11.1	13.9	2.4	6.6	10.4	13.1
Others									
Ratio of profit before tax to total assets (ROA)	%	4.2	8.5	12.3	14.5	2.5	6.5	10.6	13.6
Ratio of operating profit to revenue	%	42.6	42.6	41.2	35.2	28.8	35.5	38.7	35.7
Ratio of equity attributable to owners of parent to total assets	%	85.8	85.8	87.7	87.2	87.9	88.7	88.7	88.7
Dividend payout ratio	%	-	-	-	28.6	-	-	-	30.6

*1. Revenue for FY2023 includes Lump-sum income for transfer of ADHD drug.
2. Excluding royalty income, starting from FY2022
3. The Company conducted a 3-for-1 stock split of shares of common stock, effective October 1, 2024. Basic earnings per share and Diluted earnings per share were calculated under the assumption that the stock split had been conducted at the beginning of FY2023.

7. Employees

		FY2023				FY2024			
		As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31
Employees	Persons	5,719	5,325	4,957	4,959	5,001	4,990	4,944	4,955

* The decrease in FY2023 is mainly due to the fact that Shionogi Business Partner Co., Ltd. is no longer a consolidated subsidiary following the formation of a joint venture with Accenture Japan Ltd. in July 2023 and the implementation of a special early retirement program with a retirement date of October 31, 2023.

8. Capital investments and Depreciation and Amortization

(Billions of yen)

	FY2023	FY2024	Change	Change(%)	FY2024 forecast	Progress(%)	FY2025 forecast	Change
Investments in equipments	14.9	12.3	(2.6)	(17.5)	12.5	98.6	31.0	18.8
Depreciation and Amortization	18.3	20.9	2.6	14.2	20.6	101.7	22.1	1.1
Property, plant andequipment	10.3	11.7	1.4	14.0				
Intangible assets	5.9	6.2	0.3	5.1				
Right-of-use assets	2.2	2.7	0.5	24.5				
Investment property	0.0	0.4	0.3	-				

9. Exchange rate

	FY2023		FY2024		FY2025 forecast
	CR	AR	CR	AR	AR
USD	151.33	144.59	149.53	152.62	147
GBP	191.13	181.72	193.76	194.73	187
EUR	163.24	156.76	162.05	163.88	153

10. Pipeline (as of May 12, 2025)

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
Infectious disease	Cefiderocol Tosilate Sulfate Hydrate [US, Japan: Fetroja®] [EU:Fetcroja®]	Cell-wall synthesis inhibition (injection)	Gram-negative infection(pediatric)	Phase III	In-house	In-house
			Gram-negative infection	Phase III NDA submission: China (Aug. 2024) MAA submission: Australia (Dec. 2024)	In-house	In-house
	Baloxavir marboxil [USA:Xofluza™] [Japan:Xofluza®]	Cap-dependent endonuclease inhibition (oral, granule)	Influenza virus infection(body weight <20kg)	NDA submission: Japan (Aug. 2018)	In-house	In-house/ Roche (Switzerland)
	S-268019 [Japan:Covgoze®]	Vaccine (muscular injection)	Prevention of COVID-19 (Adolescent)	Phase II/III	In-house	In-house
			Prevention of COVID-19 (Children)	Phase I/II/III	In-house	In-house
	S-268023	Vaccine (muscular injection)	Prevention of COVID-19	Phase III	In-house	In-house
	S-268024	Vaccine (muscular injection)	Prevention of COVID-19	Phase III	In-house	In-house
	Ensitrelvir Fumaric Acid [Japan:Xocova®]	3CL protease inhibitor (oral)	Treatment of COVID-19 (12 years old and older)	Phase III NDA submission: Taiwan (Jan. 2025) NDA withdrawal: Singapore	In-house	Japan, global, Taiwan: In-house South Korea: In-house/Ildong Singapore: In-house/Juniper
			Treatment of COVID-19 (Children, 5 to 11 years)	Phase III	In-house	In-house
			Post exposure prophylaxis of COVID-19	NDA submission: Japan (Mar. 2025)	In-house	In-house
	Olorofim	Dihydroorotate dehydrogenase (DHODH) inhibition (oral)	Invasive aspergillosis	Phase III	F2G (UK)	In-house/ F2G
	S-892216	3CL protease inhibitor (oral)	Treatment of COVID-19	Phase II	In-house	In-house
		3CL protease inhibitor (long-acting injection)	Pre exposure prophylaxis of COVID-19	Phase I	In-house	In-house
	S-337395	RNA dependent RNA polymerase inhibitor (oral)	Treatment of RSV infection	Phase II	In-house/ UBE	In-house/ UBE
	S-743229	Cell-wall synthesis inhibition (oral)	Complicated urinary tract infections, including pyelonephritis	Phase I	In-house/ Qpex	In-house
	S-649228	Cell-wall synthesis inhibition (injection)	Gram-negative infection	Phase I	In-house/ Qpex	In-house
QOL Diseases	Naldemedine tosilate [Japan:Symproic®] [EU:Rizmoic®]	Peripheral opioid receptor antagonist (oral, powder)	Opioid-induced constipation (pediatric)	Phase I/II	In-house	In-house
		Peripheral opioid receptor antagonist (oral)	Opioid-induced constipation	Phase III	In-house	In-house
	Zuranolone	$GABA_A$ receptor positive allosteric modulator (oral)	Depression	NDA submission: Japan (Sep. 2024)	Sage (USA)	In-house/ Sage
	SDT-001 [Japan:ENDEAVORRIDE®]	Treatment digital application based on cerebral mechanism	Treatment of ADHD (pediatric)	Approval: Japan (Feb. 2025)	Akili (USA)	In-house/ Akili
	Zatolmilast	PDE4D negative allosteric modulator (oral)	Fragile X syndrome	Phase II/III	Tetra (USA)	In-house
			Jordan syndrome	Phase II	Tetra (USA)	In-house
			Alzheimer's disease	Phase II	Tetra (USA)	In-house
	Resiniferatoxin	TRPV1 agonist (Intra-articular injection)	Pain associated with osteoarthritis of knee	Phase III	Grünenthal (Germany)	Grünenthal
	S-151128	Nav1.7 inhibitor (injection)	Chronic pain	Phase I	In-house	In-house
	ADR-001	Human mesenchymal stem cells (injection)	Decompensated liver cirrhosis	Phase I/II	Rohto (Japan)	In-house/ Rohto
	S-309309	Monoacylglycerol acyltransferase 2 inhibitor (oral)	Obesity	Phase II	In-house	In-house
	S-588410	Cancer peptide vaccine (injection)	Esophageal cancer	Phase III	OncoTherapy Science, Inc. (Japan)	In-house
		Cancer peptide vaccine (injection)	Bladder cancer	Phase II	OncoTherapy Science, Inc. (Japan)	In-house
	S-488210	Cancer peptide vaccine (injection)	Head and neck squamous cell carcinoma	Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house
	S-588210	Cancer peptide vaccine (injection)	Solid tumor	Phase I	OncoTherapy Science, Inc. (Japan)	In-house

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
QOL Diseases	S-222611 (Epertinib)	HER2/EGFR dual inhibitor (oral)	Malignant tumor	Phase I/II	In-house	In-house
	SR-0379	Promote granulation formation (topical)	Cutaneous ulcer (Pressure ulcer, Diabetic ulcer)	Phase III	FunPep (Japan)	In-house/ FunPep
	Redasemtide Trifluoroacetate	Mobilization of mesenchymal stem cells (MSCs) to peripheral blood (injection)	Stroke	Phase IIb	StemRIM (Japan)	In-house
		Mobilization of mesenchymal stem cells (MSCs) to peripheral blood (injection)	Epidermolysis bullosa	Phase II	StemRIM (Japan)	In-house
	S-531011	anti-CCR8 antibody (injection)	Solid tumor	Phase Ib/II	In-house	In-house
	S-740792	New mechanism of action (oral)	Walking impairment associated with multiple sclerosis	Phase I	In-house	In-house
	SASS-001 (S-600918 + Concomitant drug X)	P2X3 receptor inhibitor (oral) + Mechanism of Concomitant drug	Sleep apnea with a central component	Phase II	S-600918: In-house	Shionogi-Apnimed Sleep Science, LLC (USA)
	S-606001	Glycogen synthase 1 (GYS1) inhibitor (oral)	Pompe disease	Phase I	Maze (USA)	In-house
	SDS-881	AI Programmed Medical Device for Conversational Cognitive Function Testing	Cognitive impairment in dementia	Phase III	FRONTEO (Japan)	In-house

<Out-Licensing Activity>

Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
Baloxavir marboxil [USA:Xofluza™] [Japan:Xofluza®]	Cap-dependent endonuclease inhibition (oral)	Influenza virus infection (pediatric, < 1 year old)	NDA Submission: EU (Jun. 2024)	In-house	In-house/ Roche (Switzerland)
		Influenza virus infection (transmission)	NDA submission: USA (Nov. 2024)	In-house	In-house/ Roche (Switzerland)
S-723595 (TLC-3595)	Acetyl-CoA carboxylase 2 inhibitor (oral)	Type 2 diabetes	Phase IIa	In-house	OrsoBio, Inc. (USA)
S-365598	Integrase inhibitor (ultra long-acting injection)	HIV infection	Phase IIa	In-house	SHIONOGI-ViiV Healthcare LLC

Since January 31, 2025

Change	Ensitrelvir Fumaric Acid(Prevention): Phase III→Japan: NDA submission
	S-892216(oral): Phase I→ Phase II
	SDT-001: Japan: NDA submission→ Approval
Add	S-268024: Phase III
	S-892216(long-acting injection): Phase I
	SDS-881 : Phase III